Advertisement

Liver Diseases pp 533-543 | Cite as

Contrast Enhanced MR imaging of Liver

  • Ran-Chou Chen
  • Chen-Te Chou
  • Yung-Liang Wan
Chapter

Abstract

Contrast enhanced dynamic MRI is one of the best noninvasive imaging modalities in diagnosis of liver lesions. Recent progress of the MR scanner, software techniques and new contrast agents have increased the effectiveness and accuracy in detecting and characterizing liver disease, especially focal hepatic lesions.

Currently, the extracellular contrast agent Gd-DTPA and the combined agent Gd-EOB-DTPA are the most frequently used contrast media in clinical practice. The diagnosis of hepatocellular carcinoma could be established by the typical arterial enhancement and washout phenomenon in the venous/delayed phases. Furthermore, Gd-EOB-DTPA provides quantitative functional information, help in staging liver fibrosis and provide additional tumor information in hepatobiliary images. Therefore, the contrast enhanced MR is widely used in the diagnosis of diffuse liver disease and focal hepatic lesions. However, future studies are still needed to continuously improve the diagnostic accuracy.

Keywords

Gd-DTPA Gd-EOB-DTPA Contrast enhanced dynamic MR FNH HCC 

References

  1. 1.
    Lee JM, Yoon JH, Joo I, Woo HS. Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer. 2012;1(1):22–40.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Fahlenkamp UL, Wagner M, Nickel D, et al. Novel dynamic hepatic magnetic resonance imaging strategy using advanced parallel acquisition, rhythmic breath-hold technique, and gadoxetate disodium enhancement. Investig Radiol. 2016;51(1):33–40.CrossRefGoogle Scholar
  3. 3.
    Chen BB, Murakami T, Shih TT, et al. Novel imaging diagnosis for hepatocellular carcinoma: consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2015;4(4):215–27.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang YC, Chou CT, Lin CP, Chen YL, Chen YF, Chen RC. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images. PLoS One. 2017;12(3):e0174594.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Brown JJ, vanSonnenberg E, Gerber KH, Strich G, Wittich GR, Slutsky RA. Magnetic resonance relaxation times of percutaneously obtained normal and abnormal body fluids. Radiology. 1985;154(3):727–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Kenney PJ, Sobol WT, Smith JK, Morgan DE. Computed model of gadolinium enhanced MRI of breast disease. Eur J Radiol. 1997;24(2):109–19.PubMedCrossRefGoogle Scholar
  8. 8.
    Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 1996;6(1):162–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR. Gadolinium tissue deposition in brain and bone. Magn Reson Imaging. 2016;34(10):1359–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196(2):W138–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Neri E, Bali MA, Ba-Ssalamah A, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016;26(4):921–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology. 2001;218(1):27–38.PubMedCrossRefGoogle Scholar
  14. 14.
    Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics. 2006;26(6):1621–36.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011;1(1):35–40.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Sahani DV, O’Malley ME, Bhat S, Hahn PF, Saini S. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results. J Comput Assist Tomogr. 2002;26(2):216–22.PubMedCrossRefGoogle Scholar
  17. 17.
    Rofsky NM, Earls JP. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging. Magn Reson Imaging Clin N Am. 1996;4(1):73–85.PubMedGoogle Scholar
  18. 18.
    Hope MD, Hope TA, Zhu C, et al. Vascular imaging with ferumoxytol as a contrast agent. AJR Am J Roentgenol. 2015;205(3):W366–73.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6(1):43–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: Part 2, Protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol. 2010;195(1):29–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Hopkinson G, Lockwood P, Dolbear G. Evaluation of an equilibrium phase free-breathing dynamic contrast-enhanced MRI prototype sequence compared to traditional breath-held MRI acquisition in liver oncology patients. Radiography. 2018;24(3):211–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med. 2002;47(1):135–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Taouli B, Johnson RS, Hajdu CH, et al. Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. Am J Roentgenol. 2013;201(4):795–800.CrossRefGoogle Scholar
  24. 24.
    Haradome H, Grazioli L, Tsunoo M, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging. 2010;32:334–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Chandarana H, Feng L, Ream J, et al. Respiratory motion-resolved compressed sensing reconstruction of free-breathing radial acquisition for dynamic liver MRI. Investig Radiol. 2015;50(11):749–56.CrossRefGoogle Scholar
  26. 26.
    Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging. 2013;13(4):567–79.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    de Graaf W, Häusler S, Heger M, et al. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011;54(4):738–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21(4):877–92.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. AJR Am J Roentgenol. 2000;174(3):691–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Choi J-Y, Lee J-M, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–54.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Li R, Cai P, Ma KS, Ding SY, Guo DY, Yan XC. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci Rep. 2016;6:26772.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ran-Chou Chen
    • 1
    • 2
  • Chen-Te Chou
    • 2
    • 3
    • 4
    • 5
  • Yung-Liang Wan
    • 6
    • 7
  1. 1.Commissioner, Department of HealthNew Taipei City GovernmentNew Taipei CityTaiwan
  2. 2.Department of Biomedical Imaging and Radiological SciencesNational Yang-Ming UniversityTaipei CityTaiwan
  3. 3.Department of RadiologyChanghua Christian HospitalChanghua CityTaiwan
  4. 4.School of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  5. 5.Department of Molecular Biotechnology, College of Biotechnology and BioresourcesDayeh UniversityChanghua CityTaiwan
  6. 6.Department of Medical Imaging and Radiological Sciences, College of MedicineChang Gung UniversityTaoyuan CityTaiwan
  7. 7.Department of Medical Imaging and InterventionLinkou Chang Gung Memorial HospitalTaoyuan CityTaiwan

Personalised recommendations